<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2016.62015</article-id><article-id pub-id-type="publisher-id">ACM-17778</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20160200000_99911504.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  代谢组学在结直肠癌早期诊断中的应用进展
  Application and Progress of Metabolic Proteomics in Early Diagnosis of Colorectal Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>明浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>萍</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>文炜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>雪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>瑞玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>瑞玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>火箭军总医院，消化内科，北京</addr-line></aff><aff id="aff3"><addr-line>火箭军总医院，药剂科，北京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>13</day><month>06</month><year>2016</year></pub-date><volume>06</volume><issue>02</issue><fpage>81</fpage><lpage>87</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   尽管目前结直肠癌治疗方法不断的创新与发展，其预后仍然较差，尤其是晚期结直肠癌，如病人可以早期诊断并治疗其5年生存率可以显著提高。结直肠癌不仅影响人均寿命，也对社会经济造成巨大负担。传统结直肠癌筛查方法包括便潜血检测及结肠镜检查，便潜血检测其敏感性及特异性较低；而结肠镜具有侵入性，花费较高且存在一定风险。这两项方法并不能满足结直肠癌早期诊断的要求，因此迫切需要一种筛查方法早期发现、早期诊断结直肠癌，延长结直肠癌患者生存期，改善其预后。继基因组学、转录组学、蛋白质组学之后新兴的一门“组学”称为代谢组学，其对生物体内参与生化反应成千上万中间产物及终产物进行动态的定性定量分析，可以反应生物不同生理、病理及生长状态。近期研究发现代谢组学在肿瘤的研究中具有广泛的用途，包括肿瘤早期诊断、分期、评估疗效和预测预后等，其中包括关于结直肠癌的研究，这为建立有效、稳点、可靠的结直肠癌早期诊断方法提供了新的思路。本文对代谢组学在结直肠癌中早期诊断的研究进展作一综述。 Although the treatment methods of colorectal cancer have experienced constant innovations and development, the prognosis remains poor, especially among patients with advanced colorectal can-cer. Early diagnosis and treatment may significantly improve the five-year survival rate of these pa-tients. Colorectal cancer not only shortens mean life span, but also percolates the social economy. Traditional screening methods of colorectal cancer mainly include fecal occult blood detection and colonoscopy. Fecal occult blood detection focuses on the sensitivity of colerectal cancer but has low specificity, while colonoscopy is invasive, expensive and subject to some risk. These two methods fail to meet the requirements for early diagnosis of colorectal cancer. Therefore, there is an urgent need for a screening method for early detection and early diagnosis of colorectal cancer in order to prolong the survival time of patients with colorectal cancer and improve the prognosis. Following genomics, transcriptomics and proteomics, metabolomics comes into being as a new “omics” that carries out dynamic, quantitative and qualitative analyses of thousands of intermediate products and end products entering into a sequence of biochemical reactions, thus reflecting various physiological, pathological and growth statuses. Recent studies have found that metabolomics had a wide range of uses in cancer researches, including early tumor diagnosis, staging, therapeutic evaluation, prognosis prediction and so on; researchers on colorectal cancer also included. This provides new ways for establishing effective, stable and reliable methods of early diagnosis of colorectal cancer. This review mainly presents an introduction to the concept and research techniques of metabolomics, as well as advances in its applications in early diagnosis of colorectal cancer.
    
  
 
</p></abstract><kwd-group><kwd>结直肠癌，代谢组学，筛查，诊断, Colorectal Cancer</kwd><kwd> Metabonomics</kwd><kwd> Screening</kwd><kwd> Diagnosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>代谢组学在结直肠癌早期诊断中的应用进展<sup> </sup></title><p>刘明浩<sup>1</sup>，李萍<sup>2</sup>，胡文炜<sup>1</sup>，李雪<sup>1</sup>，王瑞玲<sup>1*</sup></p><p><sup>1</sup>火箭军总医院，消化内科，北京</p><p><sup>2</sup>火箭军总医院，药剂科，北京</p><disp-formula id="hanspub.17778-formula15"><graphic xlink:href="http://html.hanspub.org/file/1-1570213x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年5月14日；录用日期：2016年6月6日；发布日期：2016年6月13日</p><disp-formula id="hanspub.17778-formula16"><graphic xlink:href="http://html.hanspub.org/file/1-1570213x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>尽管目前结直肠癌治疗方法不断的创新与发展，其预后仍然较差，尤其是晚期结直肠癌，如病人可以早期诊断并治疗其5年生存率可以显著提高。结直肠癌不仅影响人均寿命，也对社会经济造成巨大负担。传统结直肠癌筛查方法包括便潜血检测及结肠镜检查，便潜血检测其敏感性及特异性较低；而结肠镜具有侵入性，花费较高且存在一定风险。这两项方法并不能满足结直肠癌早期诊断的要求，因此迫切需要一种筛查方法早期发现、早期诊断结直肠癌，延长结直肠癌患者生存期，改善其预后。继基因组学、转录组学、蛋白质组学之后新兴的一门“组学”称为代谢组学，其对生物体内参与生化反应成千上万中间产物及终产物进行动态的定性定量分析，可以反应生物不同生理、病理及生长状态。近期研究发现代谢组学在肿瘤的研究中具有广泛的用途，包括肿瘤早期诊断、分期、评估疗效和预测预后等，其中包括关于结直肠癌的研究，这为建立有效、稳点、可靠的结直肠癌早期诊断方法提供了新的思路。本文对代谢组学在结直肠癌中早期诊断的研究进展作一综述。</p><p>关键词 :结直肠癌，代谢组学，筛查，诊断</p><disp-formula id="hanspub.17778-formula17"><graphic xlink:href="http://html.hanspub.org/file/1-1570213x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>结直肠癌(colorectal cancer, CRC)在欧洲是排名第2位的常见肿瘤，在各种肿瘤所引起的死亡原因中排名第2位，2007年至2008年新发43600例结直肠癌 [<xref ref-type="bibr" rid="hanspub.17778-ref1">1</xref>] 。CRC发病率及死亡率高，但其疾病进展过程缓慢，尤其其癌前病变(如结直肠腺瘤)如早期发现可以完全切除从而防止结直肠癌的发生，最近欧美发布的结直肠息肉切除术后随访指南平均随访时间3~10年也间接提示CRC发展过程缓慢 [<xref ref-type="bibr" rid="hanspub.17778-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.17778-ref3">3</xref>] ，文献报道对CRC要进行大规模人群的筛查，可以显著减少结直肠癌发病率及死亡率 [<xref ref-type="bibr" rid="hanspub.17778-ref4">4</xref>] 。将人群分为平均风险组及高风险组两类进行筛查，每组的筛查方法不同，前者定义为年龄大于50岁不伴结直肠癌个人史及家族史、不伴结直肠息肉、炎症性肠病；后者是指伴结直肠癌家族史或个人史、伴结肠息肉、炎症性肠病。此外，还有一类特殊风险人群，指具有遗传风险或遗传肿瘤综合征，如家族性腺瘤性息肉病及遗传性非息肉病性CRC [<xref ref-type="bibr" rid="hanspub.17778-ref5">5</xref>] 。高风险组及特殊风险人群应直接进行结肠镜进行筛查。而平均风险组人群规模巨大，结肠镜具有侵入性及风险性，并且经济成本高，因此不适于大规模人群筛查，因此需要一种低侵入性、低成本的筛查方法应用于该组人群 [<xref ref-type="bibr" rid="hanspub.17778-ref6">6</xref>] 。基于以上原因，近几年大量学者致力于研究出新的高效、可靠结直肠癌筛查方法。</p><p>目前关于“组学”研究包括基因组学、转录组学、蛋白质组学及代谢组学等，尤其是对小分子代谢物质研究的代谢组学，随着检验技术及分析方法的不断更新完善，其在临床医学、细胞生物学方面有着广泛的应用前景 [<xref ref-type="bibr" rid="hanspub.17778-ref7">7</xref>] 。基因组学重点研究基因多态性及基因突变与疾病相关性，也是起步最早、报道最多的基础研究。转录组学是针对mRNA进行研究，其反应基因组学中功能性基因的表达情况。蛋白组学研究蛋白质表达情况及其功能，例如蛋白的异常表达、蛋白磷酸化及蛋白相互作用等。代谢组学检测生物代谢中小分子代谢物质，其更能反映生物代谢终点事件，结合上述三种组学研究，可以更好的阐述疾病发生的机制，尤其在肿瘤发生、发展方面 [<xref ref-type="bibr" rid="hanspub.17778-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.17778-ref9">9</xref>] 。代谢组学反应各项组学的终点，等同于基因表型的终点，疾病的发生多数是基因因素、环境因素等共同作用的结果，代谢产物易受外界因素的影响，如环境及饮食因素，而基因组学不易受到外界因素的影响；此外，体内各类酶活性的变化也会影响代谢产物的浓度，因此，代谢谱反应其上游基因组学、转录组学、蛋白组学最本质的结果，细胞代谢谱相比于细胞基因谱、蛋白谱更能说明细胞当前的状态，其可以在各项其他“组学”发生变化之前出现代谢途径及产物异常，也就是在疾病早期发生改变，该特点使其在CRC早期诊断方面具有很好的应用前景 [<xref ref-type="bibr" rid="hanspub.17778-ref10">10</xref>] 。</p></sec><sec id="s4"><title>2. 代谢组学</title><p>代谢组学对生物体内参与生化反应成千上万中间产物及终产物进行动态的定性定量分析，其可以应用于包括肿瘤在内的多种疾病的诊断 [<xref ref-type="bibr" rid="hanspub.17778-ref11">11</xref>] 。代谢组学是一门跨学科组学，其基于基础科学(生物化学、生物学)，依靠生物信息学、流行病学及临床医学，多学科间的协作才能更好的使代谢组学应用于临床诊断。“代谢组”一词首先是于1998年被报道，该研究检测了生物样本中全部的代谢产物 [<xref ref-type="bibr" rid="hanspub.17778-ref12">12</xref>] ，随后于1999年Nicholson等人提出了代谢组学概念 [<xref ref-type="bibr" rid="hanspub.17778-ref13">13</xref>] ，隔年Fiehn等人也提出了同样的概念 [<xref ref-type="bibr" rid="hanspub.17778-ref14">14</xref>] ，逐渐“代谢组学”被学术界所认可。人类代谢组学中代谢物数量大约在1万至10万之间，但目前人类代谢物数据库中只存录了大约4万余种，说明代谢组学具有广阔的研究空间 [<xref ref-type="bibr" rid="hanspub.17778-ref15">15</xref>] 。代谢产物小分子量小且含量相对少，因此要求其方法要具有较高的敏感性及稳定性，否则将对后期数据分析造成巨大影响。目前较常用的代谢组学检测方法有核磁共振波谱(nuclear magnetic resonance, NMR)和质谱分析法(Mass spectrometry, MS)。NMR利用核内质子在磁场中的磁偶自旋或共振频率的不同来检测代谢物，其敏感性较低，核磁共振氢谱是最常用的方法；MS是通过气相/液相色谱法分离代谢物，将代谢物离子化后，根据其质荷比的不同进行检测，其特点为高通量及高敏感性，主要包括气相色谱–质谱联用、液相色谱–质谱联用和毛细管电泳–质谱联用等 [<xref ref-type="bibr" rid="hanspub.17778-ref16">16</xref>] 。代谢组学按照研究代谢物是否明确可分为目标性研究和分目标性研究，前者是指实验前已确定某些代谢物质(通常为10~100种)针对性的进行检测；后者是指应用特定方法检测生物体内所有已知代谢产物后再进行统计分析 [<xref ref-type="bibr" rid="hanspub.17778-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.17778-ref18">18</xref>] 。人类代谢组学可以反应细胞在蛋白质及基因水平发生改变后代谢终点产物的差异 [<xref ref-type="bibr" rid="hanspub.17778-ref19">19</xref>] ，其可能比基因组学及蛋白组学提供更多细胞表型改变信息，更好的阐明细胞间基因、蛋白差异表达的机制。</p><p>蛋白组学和基因组学已经发展为肿瘤研究的常规方法，其研究结果应用于肿瘤的早期诊断、肿瘤分型分期、对治疗反应预测及评估预后，并逐步发展为肿瘤治疗手段 [<xref ref-type="bibr" rid="hanspub.17778-ref20">20</xref>] ，近年报道了大量的蛋白组学及基因组学肿瘤相关研究 [<xref ref-type="bibr" rid="hanspub.17778-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.17778-ref22">22</xref>] ，而代谢组学优于基因及蛋白组学，代谢过程可以直接反应细胞功能，对肿瘤细胞研究更具有价值 [<xref ref-type="bibr" rid="hanspub.17778-ref19">19</xref>] 。</p></sec><sec id="s5"><title>3. 结直肠癌传统筛查方法</title><p>目前临床传统的CRC筛查方法包括粪便潜血实验、结肠镜、乙状结肠镜及影像学(如气钡双重对比造影)检查。粪便潜血实验是肠道肿瘤最常用的筛查方法，其无创、低成本，相对其他传统筛查方式患者更加容易接受。Hewitson等人在2008年总结了四项应用粪便潜血试验进行结直肠癌筛查的随机对照实验进行meta分析，该meta分析总共包括约32万例患者，结果示应用粪便潜血试验进行结直肠癌筛查使该人群结直肠癌相对死亡风险减少16% [<xref ref-type="bibr" rid="hanspub.17778-ref23">23</xref>] 。不过，该方法特异性较低，为进一步提高其特异性，学者改良粪便潜血检测方式，以抗人血红蛋白抗体作用一抗对粪便进行免疫组化检验，该方法相对过氧化物酶方法检测亚铁血红素特异性有一定程度提高，但仍不能满足大规模筛查结直肠癌的要求，造成大量患者进行了本不需要的结肠镜检查 [<xref ref-type="bibr" rid="hanspub.17778-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.17778-ref25">25</xref>] 。基于目前研究，三分之二的结直肠癌发生于直肠及乙状结肠，因此乙状结肠镜可以作为一种非侵入性且准确性高的筛查方法，但其检查具有局限性，不能发现结肠其他位置肿瘤，因此不常规推荐作为结直肠癌筛查方法 [<xref ref-type="bibr" rid="hanspub.17778-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.17778-ref27">27</xref>] 。</p><p>结肠镜仍然是诊断结直肠息肉及肿瘤的金标准。文献报道切除结直肠息肉并随访可以使结直肠癌死亡率降低53% [<xref ref-type="bibr" rid="hanspub.17778-ref28">28</xref>] 。虽然结肠镜无论对于结直肠肿瘤的诊断、治疗具有很好的效果，但其人群依从性低、高成本、侵入性及罕见严重并发症(致命性穿孔、出血并发症发生率0.1%~0.3%)等特点，仍不能广泛应用于人群筛查 [<xref ref-type="bibr" rid="hanspub.17778-ref6">6</xref>] 。Vining等最早报道了CT仿真内镜检查的临床应用。该技术是应用计算机虚拟现实技术与现代医学影像结合后产生的一种新的无创伤检查手段 [<xref ref-type="bibr" rid="hanspub.17778-ref29">29</xref>] ，可以替代气钡双重造影对全结肠进行观察。Fenlon等人报道在结直肠癌高风险人群中，CT仿真内镜对结肠息肉检出的敏感性为71%，不过该敏感性与息肉大小有直接关系，如息肉直接在1 mm~5 mm之间，其敏感性下降为55%；如息肉直径在6 mm~9 mm或者10 mm以上，其敏感性显著提高(分别为82%，91%；P = 0.001) [<xref ref-type="bibr" rid="hanspub.17778-ref30">30</xref>] 。但该检查的缺点是受检人群暴露于辐射及成本高，仍不适用于人群筛查。</p><p>现有的结直肠癌临床检查手段均不适合对大规模人群进行筛查，对受检者尿液、呼出气体、血清、粪便应用系统生物学方法进行检测是近些年迅速发展的新技术，多项研究结果证实，代谢组学进行结直肠癌早期筛查具有广阔的临床应用前景。</p></sec><sec id="s6"><title>4. 代谢组学在结直肠癌中的应用</title><p>随着对代谢组学认识的深入，近些年代谢组学应用在CRC诊断方面的研究也日益增多，众多文献报道了以CRC患者血清、呼出气体、尿液、粪便及肿瘤组织作为标本，进行代谢组学检测及分析，均提示代谢组学可以为CRC早期诊断提供潜在的分子标志物。Ikeda等人报道应用代谢组学方法检测结直肠癌及健康志愿者血清中代谢产物差别，结果发现两组间L-聚乙内酰脲，葡萄醛内酯及谷氨酰胺含量存在显著差异，应用其诊断结直肠癌敏感性为54.5%~81.8%，特异性为6.7%~91.6% [<xref ref-type="bibr" rid="hanspub.17778-ref31">31</xref>] 。最近，日本学者以血清为标本建立了一种结直肠癌代谢组学早期诊断模型，该研究纳入了60例结直肠癌患者和60例健康志愿者，对其血清代谢谱检测后建立了一个由2-羟基丁酸、天冬氨酸、犬尿氨酸和胱胺４种代谢产物质组成的诊断模型，该模型的受试者工作特征曲线下面积、灵敏度、特异度和准确率分别为0.9097、85.0%、85.0%和85。0%，而传统血清标志物CEA及CA19-9的灵敏度、特异度和准确率分别为35.0%和16.7%、96.7%和100%、65.8%和58.3%；之后再次纳入59名结直肠癌患者和63名健康志愿者组成测试组对该模型进行了检验，在测试组中其灵敏度、特异度和准确率分别为83.1%、81.0%和82.0%。该预测模型对0~II期结直肠癌也有很好的诊断效果，其敏感度可高达82.8%。如经过大规模临床试验验证其可靠性，可以作为理想的结直肠癌筛查手段 [<xref ref-type="bibr" rid="hanspub.17778-ref32">32</xref>] 。Ritchie等人研究发现在结直肠癌患者血清中代谢产物羟化不饱和超长链脂肪酸浓度显著异常，并且该代谢产物很容易在结直肠癌患者血清中被检出，对结直癌诊断具有很好的敏感性及特异性 [<xref ref-type="bibr" rid="hanspub.17778-ref33">33</xref>] 。结肠息肉为CRC高风险因素，一项研究发现多种代谢产物在结肠息肉患者血清中浓度显著改变，并且缬氨酸与结肠息肉独立相关，进一步提示代谢组学对CRC早期诊断有着很好的应用前景 [<xref ref-type="bibr" rid="hanspub.17778-ref34">34</xref>] 。呼气检测是指应用特定仪器检测患者呼吸时呼出的化合物，根据化学成分的不同，可疾病进行诊断，是筛查结直肠癌很好的方法，因其标本获取方便、无侵入性、成本较低且患者对该检测依从性较好 [<xref ref-type="bibr" rid="hanspub.17778-ref35">35</xref>] 。挥发有机复合物(Volatile organic compounds, VOCs)于1971年由Pauling等人首次分离鉴定，应用呼气检测方法发现肿瘤患者呼出的VOCs与健康人存在显著不同，考虑可能机制为肿瘤患者体内基因突变导致蛋白表达异常，导致细胞膜多元不饱和脂肪酸氧化作用不同于正常细胞，继而产生不同VOCs [<xref ref-type="bibr" rid="hanspub.17778-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.17778-ref37">37</xref>] 。另一项类似研究报道检测结直肠癌患者呼出气体中58种VOCs，确定了15种VOCs显著区别于健康人群，其对结直肠癌诊断的敏感性为86%，特异性为83%，准确性为85% [<xref ref-type="bibr" rid="hanspub.17778-ref38">38</xref>] 。尿液和血清同样是理想的结直肠癌筛查代谢组学标本，Silva等人检测了33例肿瘤患者(包括CRC)尿液中挥发性有机代谢物浓度，与健康对照组相比，2-甲基-3-苯基-2-丙烯醛、p-甲基异丙基苯、苯甲醚、4-甲基-苯酚及1,2-二氢-1,1,6-三甲基-萘在肿瘤患者尿液中浓度显著增高 [<xref ref-type="bibr" rid="hanspub.17778-ref39">39</xref>] 。Cheng等人检测一组结直肠患者尿液代谢谱，与正常对照组相比，其中柠檬酸、马尿酸盐、p-甲酚、2-氨基丁酸、豆蔻酸盐,腐胺和犬尿氨酸显著改变，应用该其中代谢产物建立模型亦可对结直肠癌进行诊断 [<xref ref-type="bibr" rid="hanspub.17778-ref40">40</xref>] 。Monle&#243;n检测结直肠癌患者粪便中代谢谱，与正常对照组相比多种短链脂肪酸浓度显著降低，如乙酸和丁酸，该方法标本容易获得、经济成本低且可重复性高，可以作为潜在理想的结直肠癌早期诊断方法 [<xref ref-type="bibr" rid="hanspub.17778-ref41">41</xref>] 。另一项研究，检测了CRC组织中全部已知的代谢产物 [<xref ref-type="bibr" rid="hanspub.17778-ref16">16</xref>] ，结果发现肿瘤组织中代谢谱与正常结直肠组织中显著不同，确定一系列肿瘤组织代谢谱分子标志物。代谢途径谱反映出在CRC细胞中多种生化进程异常，如糖酵解、克雷伯氏循环、渗透调节、类固醇生物合成,类二十烷酸生物合成、胆汁酸合成、脂类、氨基酸和核苷酸代谢等。Ma等人检测结直肠癌患者血清中34种代谢产物后发现6种代谢产物在结直肠癌组中显著改变，应用其对结直肠癌诊断的准确率可达93.5% [<xref ref-type="bibr" rid="hanspub.17778-ref42">42</xref>] 。Ong等人应用高特异性(气象色谱/质谱联用技术、液相色谱/质谱联用技术)方法系统的检测总共26例结直肠癌组织、癌旁组织及息肉组织中代谢路径，结果发现多种氨基酸及脂质在结直肠息肉及肿瘤中代谢增高，考虑可能与肿瘤生长的高能量需求有关，而葡萄糖及肌糖在结肠息肉患者中显著消耗提示在结直肠癌早期糖酵解增加可能为肿瘤发生初期代表性改变 [<xref ref-type="bibr" rid="hanspub.17778-ref43">43</xref>] 。高迁移率蛋白A1(High Mobility Group A1, HMGA1)与CRC发生、发展密切相关，Williams等人检测HMGA1异常表达转基因小鼠结肠上皮细胞代谢谱，同时检测CRC患者肿瘤组织，癌旁组织及正常组织中代谢谱。结果13种代谢产物在转基因小鼠结肠上皮细胞及人类CRC组织中显著改变，其中包括脂肪酸代谢及细胞膜组成的重要成分。该团队还检测结肠癌细胞代谢谱，与正常结肠上皮细胞相比，其脂肪酸合成及氧化、糖分解、聚胺路径发生显著改变 [<xref ref-type="bibr" rid="hanspub.17778-ref44">44</xref>] 。研究中可以发现，脯氨酸及半胱氨酸为结肠上皮粘液糖蛋白主要成分，同时在结直肠癌代谢谱中发生显著改变。低浓度的短链脂肪酸，如乙酸和丁酸，与结直肠癌发展密切相关，可能将成为CRC有效的分子标志物。而最为理想的CRC检测方法还是粪便代谢组学方法，其经济成本低、可重复性高、并且可以高通量进行CRC筛查，但仍需要进一步大样本高质量研究验证其可行性，才能最终应用于临床。</p></sec><sec id="s7"><title>5. 结论</title><p>代谢组学作为一门新兴技术，可以通过检查患者多种生物标本，如血液、粪便、尿液、呼出气体等对结直肠癌进行诊断，获取生物标本方便，检测更加容易，是一种潜在的理想的结直肠癌早期筛查工具。不仅如此，通过对代谢组学的研究，还可以进一步寻找与结直肠癌发生发展相关的肿瘤生物标志物，为结直肠的治疗提供新的思路。但目前代谢组学与结直肠癌相关研究仍在基础阶段，尚不能应用于临床，因此，代谢组学在结直肠癌发生、发展机制中的研究可能是今后需要攻克的难题。随着对代谢组学研究的不断深入，希望其可以为结直肠癌的早期诊断提供更好的方案。</p></sec><sec id="s8"><title>文章引用</title><p>刘明浩,李 萍,胡文炜,李 雪,王瑞玲,王瑞玲. 代谢组学在结直肠癌早期诊断中的应用进展 Application and Progress of Metabolic Proteomics in Early Diagnosis of Colorectal Cancer[J]. 临床医学进展, 2016, 06(02): 81-87. http://dx.doi.org/10.12677/ACM.2016.62015</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.17778-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ferlay, J., Parkin, D.M. and Steliarova-Foucher, E. (2010) Estimates of Cancer Incidence and Mortality in Europe in 2008. European Journal of Cancer, 46, 765-781. &lt;br&gt;http://dx.doi.org/10.1016/j.ejca.2009.12.014</mixed-citation></ref><ref id="hanspub.17778-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lieberman, D.A., Rex, D.K., Winawer, S.J., et al. (2012) Guidelines for Colonoscopy Surveillance after Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 143, 844-857. &lt;br&gt;http://dx.doi.org/10.1053/j.gastro.2012.06.001</mixed-citation></ref><ref id="hanspub.17778-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hassan, C., Quintero, E., Dumonceau, J.M., et al. (2013) Post-Polypectomy Colonoscopy Surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 45, 842-851.  
&lt;br&gt;http://dx.doi.org/10.1055/s-0033-1344548</mixed-citation></ref><ref id="hanspub.17778-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Doubeni, C.A., Weinmann, S., Adams, K., et al. (2013) Screening Colonoscopy and Risk for Incident Late-Stage Colorectal Cancer Diagnosis in Average-Risk Adults: A Nested Case-Control Study. Annals of Internal Medicine, 158, 312-320. &lt;br&gt;http://dx.doi.org/10.7326/0003-4819-158-5-201303050-00003</mixed-citation></ref><ref id="hanspub.17778-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Imperiale, T.F. (2012) Noninvasive Screening Tests for Colorectal Cancer. Digestive Diseases, 30, 16-26.   
&lt;br&gt;http://dx.doi.org/10.1159/000341884</mixed-citation></ref><ref id="hanspub.17778-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Burt, R.W., Barthel, J.S., Dunn, K.B., et al. (2010) NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Journal of the National Comprehensive Cancer Network, 8, 8-61.</mixed-citation></ref><ref id="hanspub.17778-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Rochfort, S. (2005) Metabolomics Reviewed: A New “Omics” Platform Technology for Systems Biology and Implications for Natural Products Research. Journal of Natural Products, 68, 1813-1820.   
&lt;br&gt;http://dx.doi.org/10.1021/np050255w</mixed-citation></ref><ref id="hanspub.17778-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Saito, K. (2013) Phytochemical Genomics—A New Trend. Current Opinion in Plant Biology, 16, 373-380.   
&lt;br&gt;http://dx.doi.org/10.1016/j.pbi.2013.04.001</mixed-citation></ref><ref id="hanspub.17778-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Mashego, M.R., Rumbold, K., De Mey, M., et al. (2007) Micro-bial Metabolomics: Past, Present and Future Methodologies. Biotechnology Letters, 29, 1-16. &lt;br&gt;http://dx.doi.org/10.1007/s10529-006-9218-0</mixed-citation></ref><ref id="hanspub.17778-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nambiar, P.R., Gupta, R.R. and Misra, V. (2010) An “Omics” Based Survey of Human Colon Cancer. Mutation Research, 693, 3-18. &lt;br&gt;http://dx.doi.org/10.1016/j.mrfmmm.2010.07.008</mixed-citation></ref><ref id="hanspub.17778-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Fiehn, O. (2002) Metabolomics—The Link between Gen-otypes and Phenotypes. Plant Molecular Biology, 48, 155-171.  
&lt;br&gt;http://dx.doi.org/10.1023/A:1013713905833</mixed-citation></ref><ref id="hanspub.17778-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Oliver, S.G., Winson, M.K., Kell, D.B., et al. (1998) Systematic Functional Analysis of the Yeast Genome. Trends in Biotechnology, 16, 373-378. &lt;br&gt;http://dx.doi.org/10.1016/S0167-7799(98)01214-1</mixed-citation></ref><ref id="hanspub.17778-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Nicholson, J.K., Lindon, J.C. and Holmes, E. (1999) “Metabonomics”: Understanding the Metabolic Responses of Living Systems to Pathophysiological Stimuli via Multi-variate Statistical Analysis of Biological NMR Spectroscopic Data. Xenobiotica, 29, 1181-1189. &lt;br&gt;http://dx.doi.org/10.1080/004982599238047</mixed-citation></ref><ref id="hanspub.17778-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Fiehn, O., Kopka, J., Dormann, P., et al. (2000) Metabolite Profiling for Plant Functional Genomics. Nature Biotechnology, 18, 1157-1161. &lt;br&gt;http://dx.doi.org/10.1038/81137</mixed-citation></ref><ref id="hanspub.17778-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wishart, D.S., Jewison, T., Guo, A.C., et al. (2013) HMDB 3.0—The Hu-man Metabolome Database in 2013. Nucleic Acids Research, 41, D801-D807. &lt;br&gt;http://dx.doi.org/10.1093/nar/gks1065</mixed-citation></ref><ref id="hanspub.17778-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Mal, M., Koh, P.K., Cheah, P.Y. and Chan, E.C.Y. (2012) Metabo-typing of Human Colorectal Cancer Using Two- Dimensional Gas Chromatography Mass Spectrometry. Analytical and Bioanalytical Chemistry, 403, 483-493.  
&lt;br&gt;http://dx.doi.org/10.1007/s00216-012-5870-5</mixed-citation></ref><ref id="hanspub.17778-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Dettmer, K. and Hammock, B.D. (2004) Metabolomics—A New Exciting Field within the “Omics” Sciences. Environmental Health Perspectives, 112, A396-A397.</mixed-citation></ref><ref id="hanspub.17778-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Patti, G.J., Yanes, O. and Siuzdak, G. (2012) Innovation: Metabolomics: The Apogee of the Omics Trilogy. Nature Reviews Molecular Cell Biology, 13, 263-269. &lt;br&gt;http://dx.doi.org/10.1038/nrm3314</mixed-citation></ref><ref id="hanspub.17778-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Griffin, J.L. and Shockcor, J.P. (2004) Metabolic Profiles of Cancer Cells. Nature Reviews Cancer, 4, 551-561.  
&lt;br&gt;http://dx.doi.org/10.1038/nrc1390</mixed-citation></ref><ref id="hanspub.17778-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tang, B., Hsu, P.Y., Huang, T.H. and Jin, V.X. (2013) Cancer Omics: From Regulatory Networks to Clinical Outcomes. Cancer Letters, 340, 277-283. &lt;br&gt;http://dx.doi.org/10.1016/j.canlet.2012.11.033</mixed-citation></ref><ref id="hanspub.17778-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Stratton, M.R., Campbell, P.J. and Futreal, P.A. (2009) The Cancer Genome. Nature, 458, 719-724.  
&lt;br&gt;http://dx.doi.org/10.1038/nature07943</mixed-citation></ref><ref id="hanspub.17778-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Hanash, S. and Taguchi, A. (2010) The Grand Challenge to Decipher the Cancer Proteome. Nature Reviews Cancer, 10, 652-660. &lt;br&gt;http://dx.doi.org/10.1038/nrc2918</mixed-citation></ref><ref id="hanspub.17778-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Hewitson, P., Glasziou, P., Watson, E., Towler, B. and Irwig, L. (2008) Cochrane Systematic Review of Colorectal Cancer Screening Using the Fecal Occult Blood Test (Hemoccult): An Update. The American Journal of Gastroenterology, 103, 1541-1549. &lt;br&gt;http://dx.doi.org/10.1111/j.1572-0241.2008.01875.x</mixed-citation></ref><ref id="hanspub.17778-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Bandi, P., Cokkinides, V., Smith, R.A. and Jemal, A. (2012) Trends in Colorectal Cancer Screening with Home-Based Fecal Occult Blood Tests in Adults Ages 50 to 64 Years, 2000-2008. Cancer, 118, 5092-5099.</mixed-citation></ref><ref id="hanspub.17778-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">van Rossum, L.G., van Rijn, A.F., Laheij, R.J., et al. (2008) Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population. Gastroenterology, 135, 82-90.  
&lt;br&gt;http://dx.doi.org/10.1053/j.gastro.2008.03.040</mixed-citation></ref><ref id="hanspub.17778-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Selby, J.V., Friedman, G.D., Quesenberry, C.J. and Weiss, N.S. (1992) A Case-Control Study of Screening Sigmoidoscopy and Mortality from Colorectal Cancer. The New Eng-land Journal of Medicine, 326, 653-657.  
&lt;br&gt;http://dx.doi.org/10.1056/NEJM199203053261001</mixed-citation></ref><ref id="hanspub.17778-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Lieberman, D.A., Harford, W.V., Ahnen, D.J., et al. (2001) One-Time Screening for Colorectal Cancer with Combined Fecal Occult-Blood Testing and Examination of the Distal Colon. The New England Journal of Medicine, 345, 555-560. &lt;br&gt;http://dx.doi.org/10.1056/NEJMoa010328</mixed-citation></ref><ref id="hanspub.17778-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Zauber, A.G., Winawer, S.J., O’Brien, M.J., et al. (2012) Colon-oscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths. The New England Journal of Medicine, 366, 687-696.  
&lt;br&gt;http://dx.doi.org/10.1056/NEJMoa1100370</mixed-citation></ref><ref id="hanspub.17778-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ganeshan, D., Elsayes, K.M. and Vining, D. (2013) Virtual Co-lonoscopy: Utility, Impact and Overview. World Journal of Radiology, 28, 61-67. &lt;br&gt;http://dx.doi.org/10.4329/wjr.v5.i3.61</mixed-citation></ref><ref id="hanspub.17778-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Fenlon, H.M., Nunes, D.P., Schroy, P.C., Barish, M.A., Clarke, P.D. and Ferrucci, J.T. (1999) A Comparison of Virtual and Conventional Colonoscopy for the Detection of Colorectal Polyps. The New England Journal of Medicine, 341, 1496-1503. &lt;br&gt;http://dx.doi.org/10.1056/NEJM199911113412003</mixed-citation></ref><ref id="hanspub.17778-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Ikeda, A., Nishiumi, S., Shinohara, M., et al. (2012) Se-rum Metabolomics as a Novel Diagnostic Approach for Gastrointestinal Cancer. Biomedical Chromatography, 26, 548-558. &lt;br&gt;http://dx.doi.org/10.1002/bmc.1671</mixed-citation></ref><ref id="hanspub.17778-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Nishiumi, S., Kobayashi, T., Ikeda, A., et al. (2012) A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer. PLoS ONE, 7, e40459. &lt;br&gt;http://dx.doi.org/10.1371/journal.pone.0040459</mixed-citation></ref><ref id="hanspub.17778-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Ritchie, S.A., Ahiahonu, P.W., Jayasinghe, D., et al. (2010) Reduced Levels of Hydroxylated, Polyunsaturated Ultra Long-Chain Fatty Acids in the Serum of Colorectal Cancer Patients: Implications for Early Screening and Detection. BMC Medicine, 8, 13. &lt;br&gt;http://dx.doi.org/10.1186/1741-7015-8-13</mixed-citation></ref><ref id="hanspub.17778-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Chen, C., Deng, L.L., Wei, S.W., et al. (2015) Exploring Metabolic Profile Differences between Colorectal Polyp Patients and Controls Using Seemingly Unrelated Regression. Journal of Proteome Research, 14, 2492-2499.  
&lt;br&gt;http://dx.doi.org/10.1021/acs.jproteome.5b00059</mixed-citation></ref><ref id="hanspub.17778-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Patel, K. (2010) Noninvasive Tools to Assess Liver Disease. Current Opinion in Gastroenterology, 26, 227-233.  
&lt;br&gt;http://dx.doi.org/10.1097/MOG.0b013e3283383c68</mixed-citation></ref><ref id="hanspub.17778-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Kneepkens, C.M., Lepage, G. and Roy, C.C. (1994) The Potential of the Hydrocarbon Breath Test as a Measure of Lipid Peroxidation. Free Radical Biology and Medicine, 17, 127-160. &lt;br&gt;http://dx.doi.org/10.1016/0891-5849(94)90110-4</mixed-citation></ref><ref id="hanspub.17778-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Toyokuni, S. (2008) Molecular Mechanisms of Oxidative Stress-Induced Carcinogenesis: From Epidemiology to Oxygenomics. IUBMB Life, 60, 441-447. &lt;br&gt;http://dx.doi.org/10.1002/iub.61</mixed-citation></ref><ref id="hanspub.17778-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Altomare, D.F., Di Lena, M., Porcelli, F., et al. (2013) Author’s Reply: Ex-haled Volatile Organic Compounds Identify Patients with Colorectal Cancer. British Journal of Surgery, 100, 144-150. &lt;br&gt;http://dx.doi.org/10.1002/bjs.8942</mixed-citation></ref><ref id="hanspub.17778-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Silva, C.L., Passos, M. and Camara, J.S. (2011) Investigation of Urinary Volatile Organic Metabolites as Potential Cancer Biomarkers by Solid-Phase Microextraction in Combination with Gas Chromatography-Mass Spectrometry. British Journal of Cancer, 105, 1894-1904. &lt;br&gt;http://dx.doi.org/10.1038/bjc.2011.437</mixed-citation></ref><ref id="hanspub.17778-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, Y., Xie, G.X., Chen, T.L., et al. (2012) Distinct Urinary Metabolic Profile of Human Colorectal Cancer. Journal of Proteome Research, 11, 1354-1363. &lt;br&gt;http://dx.doi.org/10.1021/pr201001a</mixed-citation></ref><ref id="hanspub.17778-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Monleon, D., Morales, J.M., Barrasa, A., López, J.A., Vázquez, C. and Celda, B. (2009) Metabolite Profiling of Fecal Water Extracts from Human Colorectal Cancer. NMR in Biomedicine, 22, 342-348.  
&lt;br&gt;http://dx.doi.org/10.1002/nbm.1345</mixed-citation></ref><ref id="hanspub.17778-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Ma, Y.L., Zhang, P., Wang, F., Liu, W.J., Yang, J.J. and Qin, H.L. (2012) An Integrated Proteomics and Metabolomics Approach for Defining Oncofetal Biomarkers in the Colorectal Cancer. Annals of Surgery, 255, 720-730.  
&lt;br&gt;http://dx.doi.org/10.1097/SLA.0b013e31824a9a8b</mixed-citation></ref><ref id="hanspub.17778-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Ong, E.S., Zou, L., Li, S.X., Cheah, P.Y., Eu, K.W. and Ong, C.N. (2010) Metabolic Profiling in Colorectal Cancer Reveals Signature Metabolic Shifts during Tumorigenesis. Molecular &amp; Cellular Proteomics.  
&lt;br&gt;http://dx.doi.org/10.1074/mcp.M900551-MCP200</mixed-citation></ref><ref id="hanspub.17778-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Williams, M.D., Zhang, X., Belton, A.S., et al. (2015) HMGA1 Drives Metabolic Reprogramming of Intestinal Epithelium during Hyperproliferation, Polyposis, and Colorectal Carcinogenesis. Journal of Proteome Research, 14, 1420- 1431. &lt;br&gt;http://dx.doi.org/10.1021/pr501084s</mixed-citation></ref></ref-list></back></article>